

Haematologica
HAEMATOL/2017/183350
Version 3

Long-term follow-up of the CLL2007FMP trial evaluating fludarabine and cyclophosphamide in combination with either rituximab or alemtuzumab in previously untreated patients with chronic lymphocytic leukemia

Pierre Feugier, Thérèse Aurran, Béatrice Mahé, Remi Letestu, Florence Nguyen-Khac, Bruno Cazin, Olivier Tournilhac, Hervé Maisonneuve, Olivier Casasnovas, Alain Delmer, Véronique Leblond, Bruno Royer, Bernadette Corront, Sylvie Chevret, Roselyne Delépine, Sandrine Vaudaux, Eric Van den Neste, Marie Christine Béné, Florence Cymbalista, Damien Roos-Weil, and Stéphane Leprêtre

Disclosures: - Schering AG, Genzyme Corporation, and Amgen SA supported this trial - Pierre Feugier received grant and personal fees from Roche, Janssen, Abbvie and Gilead companies - Alain Delmer : personal fees from Abbvie, ROche, Gilead and Janssen - Remi Letestu : personal fees from Alexion, ROche and Abbvie - Bruno Royer : personal fees from Octapharma, Janssen, Celgène and Amgen - the other authors have Nothing to disclose

Contributions: PF and SL are the PI of the trial and wrote the manuscript TA, BM, BC, OT, HM, OC, AD, VL, BR, BC, EV, PF and SL participated to the recruitment of the patients and read and corrected the manuscript RL and FC performed the MRD analysis FN and DR performed cytogenetics and molecular analysis SC, MCB, RD and SD coordinated and supervised the data collection and the statistical analysis